Novel and Emerging Electrophysiological Biomarkers of Diabetic Neuropathy and Painful Diabetic Neuropathy.
Level 5 - mechanism / opinion, no new human data
Narrative literature review synthesizing electrophysiological methods without systematic meta-analysis.
PubMed 33906790 · doi:10.1016/j.clinthera.2021.03.020
What was done
The authors conducted a comprehensive literature review searching Google Scholar, PubMed, and OVID, along with reference lists and expert consensus, evaluating 145 papers. The review examined novel and emerging neurophysiological biomarkers for diagnosing, monitoring, and profiling pain mechanisms in diabetic peripheral neuropathy (DPN) and painful DPN (pDPN).
What was found
The abstract provides no quantitative pooled metrics or statistical effect sizes. It qualitatively reports that standard nerve conduction studies only assess large-fiber damage, whereas pain-related evoked potentials (via laser, heat, or targeted electrical stimuli) objectively quantify small-fiber pathway damage. Nerve excitability testing identifies axonal property changes prior to standard conduction abnormalities. Microneurography and rate-dependent depression of the Hoffmann-reflex assess peripheral and spinal pain-generation mechanisms, respectively.
Why it matters
Standard diagnostic tools frequently miss early small-fiber involvement in diabetic neuropathy. These emerging electrophysiological modalities offer mechanistic biomarkers to stratify pain pathways and serve as targeted endpoints in clinical trials.
Limits
The review relies on narrative synthesis rather than a formal systematic review or meta-analysis. The authors note that the discussed neurophysiological techniques are technically complex and currently impractical for routine, high-volume outpatient clinical settings.
Cited by
- supports Standard nerve conduction studies assess large-fiber nerve function rather than small-fiber nerve function.